Market Research Logo

Sleep Apnea - Pipeline Review, H2 2016

Sleep Apnea - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Sleep Apnea - Pipeline Review, H2 2016’, provides an overview of the Sleep Apnea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
    • The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects
    • The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Sleep Apnea
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Sleep Apnea Overview
    Therapeutics Development
    Pipeline Products for Sleep Apnea - Overview
    Pipeline Products for Sleep Apnea - Comparative Analysis
    Sleep Apnea - Therapeutics under Development by Companies
    Sleep Apnea - Therapeutics under Investigation by Universities/Institutes
    Sleep Apnea - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Sleep Apnea - Products under Development by Companies
    Sleep Apnea - Products under Investigation by Universities/Institutes
    Sleep Apnea - Companies Involved in Therapeutics Development
    Galleon Pharmaceuticals
    RespireRx Pharmaceuticals Inc.
    SK Biopharmaceuticals Co., Ltd.
    Vivus, Inc.
    Sleep Apnea - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (phentermine + topiramate) ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CX-1739 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dronabinol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GAL-475 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GAL-475 Backups - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SKL-N05 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Sleep Apnea - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sleep Apnea - Dormant Projects
    Sleep Apnea - Discontinued Products
    Sleep Apnea - Product Development Milestones
    Featured News & Press Releases
    Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
    Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016
    Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA
    May 14, 2015: VIVUS Announces Scientific Presentations
    May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
    May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
    May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists
    Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies
    Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules
    Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa
    Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa
    Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739
    Feb 02, 2011: Cortex’s Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients
    Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Sleep Apnea, H2 2016
    Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H2 2016
    Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc., H2 2016
    Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
    Sleep Apnea - Pipeline by Vivus, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Sleep Apnea - Dormant Projects, H2 2016
    Sleep Apnea - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Sleep Apnea, H2 2016
    Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report